Drugs / XTX501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07688577 | Aug 2026 → Nov 2029 expected | non-small cell lung carcinoma | Xilio Development, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XTX501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07688577 ↗ |